MSB 2.05% $1.07 mesoblast limited

BLA resubmission for children with SR-aGVHD, page-3

  1. 2,010 Posts.
    lightbulb Created with Sketch. 1171
    "JCR Pharmaceuticals in Japan is already demonstrating our manufacturing processes are extraordinarily repeatable and consistent in batch potency and effectiveness, our cells work and our manufacturing process is consistent - that is without dispute given multi-year success in Japan for successful treatment of aGVHD - Fact"

    I have absolutely no personal problem with this poster but asserting something to be a fact that is not a fact is a terrible thing to do if one wants to have a fact based discussion. Its like destroying the very meaning of the word - fact - that people will need to understand as being different to an opinion to even have a sensible discussion in the first place.

    Danger Will Robinson.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.